...
首页> 外文期刊>Memorias do Instituto Oswaldo Cruz >The promising drugs included in WHO’s Solidarity Project: a choice based in scientific knowledge and institutional competencies
【24h】

The promising drugs included in WHO’s Solidarity Project: a choice based in scientific knowledge and institutional competencies

机译:有希望的药物包括在世卫组织的团结项目中:基于科学知识和机构能力的选择

获取原文

摘要

BACKGROUND In March 2020, the World Health Organization (WHO) launched the Solidarity Program, probably the largest global initiative to encourage and support research in four promising drugs, named Remdesivir, Hydroxychloroquine, β Interferon and the combination Lopinavir / Ritonavir, to reduce the mortality of Coronavirus disease 2019 (COVID-19). OBJECTIVES Considering the potential impact of Solidarity Program to restrain the current pandemic, the present study aims to investigate whether it was designed upon indicators of scientific productivity, defined as the level of the production of new scientific knowledge and of the institutional capabilities, estimated in terms of scientific publications and technological agreements. METHODS The scientific documents on Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Coronavirus were retrieved from Scopus database while the technological agreements on coronavirus were obtained through Cortellis. As for the institutions and countries, we have considered the data on author’s affiliations in both set of data. For comparison, we included the analysis of documents related with other drugs or therapies, such as vaccines and antibodies, which were listed in a Clarivate’s report on coronaviruses research. FINDINGS Most of the analysis refers to documents on Coronavirus, the largest group. The number of documents related to WHO’s drugs are almost five times higher than in the other groups. This subset of documents involves the largest and most diverse number of institutions and countries. As for agreements, we observed a smaller number of institutions involved in it, suggesting differences between countries in terms of technical and human capabilities to develop basic and/or clinical research on coronavirus and to develop new forms or products to treat or to prevent the disease. MAIN CONCLUSIONS Hence, the results shown in this study illustrate that decisions taken by an international scientific body, as WHO, were mainly based in scientific knowledge and institutional competencies.
机译:背景技术在2020年3月,世界卫生组织(世卫组织)推出了团结计划,可能是在四种有前途的药物中鼓励和支持研究的最大全球倡议,名为Remdesivir,羟基氯喹,β干扰素和组合Lopinavir / Ritonavir,以降低死亡率2019年冠状病毒疾病(Covid-19)。目前研究旨在考虑团结计划抑制目前大流行的潜在影响,目前的研究旨在调查它是否设计在科学生产力指标后,定义为新科学知识和机构能力的生产水平,估计作者:王莹,科学出版物与技术协议。方法从Scopus数据库中检索αAvirus,Betacoronavirus,γAvirus,γAvirus的科学文献,同时通过Cortellis获得冠状病毒的技术协议。至于机构和国家,我们考虑了关于作者在两套数据中的关系的数据。为了比较,我们包括与其他药物或疗法相关的文件的分析,例如疫苗和抗体,这些文件和抗体被列入克拉敏的冠状病毒研究报告。调查结果大多数分析是指冠状病毒,最大组的文件。与谁的药物有关的文件数量差计比其他群体高的五倍。该文件的子集涉及最大,最多多样的机构和国家。至于协议,我们观察到了较少数量的机构,暗示各国在技术和人类能力方面对冠状病毒开发基本和/或临床研究以及开发新形式或产品来治疗或预防疾病的差异。因此,主要结论,本研究表明的结果说明了国际科学机构所采取的决策,因为世卫组织主要基于科学知识和机构能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号